Sangamo Therapeutics (SGMO) Set to Announce Quarterly Earnings on Tuesday

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) will be posting its quarterly earnings results after the market closes on Tuesday, November 12th. Analysts expect Sangamo Therapeutics to post earnings of ($0.07) per share for the quarter. Persons that are interested in participating in the company's earnings conference call can do so using this link.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last posted its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.01). Sangamo Therapeutics had a negative return on equity of 273.25% and a negative net margin of 2,033.69%. The company had revenue of $0.36 million for the quarter, compared to analyst estimates of $11.40 million. On average, analysts expect Sangamo Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Sangamo Therapeutics Price Performance

NASDAQ:SGMO traded up $0.42 during trading hours on Tuesday, reaching $2.16. The company had a trading volume of 9,390,785 shares, compared to its average volume of 6,779,155. Sangamo Therapeutics has a 1-year low of $0.29 and a 1-year high of $2.30. The business's 50 day moving average price is $1.02 and its 200-day moving average price is $0.74. The firm has a market cap of $449.76 million, a PE ratio of -1.57 and a beta of 1.10.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the stock. StockNews.com started coverage on shares of Sangamo Therapeutics in a report on Sunday, July 28th. They set a "sell" rating on the stock. HC Wainwright increased their target price on shares of Sangamo Therapeutics from $5.00 to $10.00 and gave the stock a "buy" rating in a research note on Tuesday. One research analyst has rated the stock with a sell rating, three have issued a hold rating and one has given a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $4.33.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.